FY2025 saw strong Commercial Pharmaceuticals growth offset by a major Manufacturing contract loss, leading to a 3% revenue decline and 15% drop in normalised EBITDA. Strategic investments in sterile manufacturing and GLP-1 are expected to drive recovery, with double-digit CER HEPS growth targeted for FY2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.